ARRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the historical short interest of Array BioPharma Inc, as measured by the Short Percentage Of Float.
This the Institutional Ownership History of Array BioPharma IncPeter Lynch prefers to buy companies with low institutional ownership.
This is the historical insider ownership of Array BioPharma Inc. It is usually better to buy companies with large insider ownership. The company insiders' interest are more aligned with external shareholders in this case.
|Holder||Position||Shares||% of Shares |
|Dr. David L. Snitman, PhD||N/A||1,502,358||1.14%||2013-07-24|
|Dr. Kevin Koch, PhD||President & CSO||786,917||0.6%||2013-07-24|
|Mr. Robert E. Conway||CEO||633,386||0.48%||2011-10-04|
|Dr. Anthony D. Piscopio,PhD||Vice President, Chemistry||553,527||0.42%||2004-04-29|
|Dr.Professor Marvin H. Caruthers,PhD||Director||177,763||0.13%||2011-06-30|
|Mr. R. Michael Carruthers||CFO||112,265||less than 0.1%||2013-07-24|
|Dr. John L. Zabriskie,PhD||N/A||30,000||less than 0.1%||2008-03-05|
|Dr. Francis J. Bullock, PhD||N/A||20,000||less than 0.1%||2010-01-14|
|Van Lunsen Gil J||Director||5,260||less than 0.1%||2007-08-09|
|Ron Squarer||N/A||4,397||less than 0.1%||2012-10-04|
|Holder||Shares||Report Date||% of Shares |
|% of Total |
|Deerfield Management Co||12,205,673||2014-09-30||9.26||1.59||43,574,000|
|Fidelity Management and Research Company||11,452,470||2014-09-30||8.69||0.01||40,885,000|
|T. Rowe Price Associates, Inc.||8,829,600||2014-09-30||6.70||0.01||31,522,000|
|Redmile Group, LLC||8,342,045||2014-09-30||6.33||3.44||29,781,000|
|T. Rowe Price Health Sciences Fund||6,730,100||2014-09-30||5.10||0.24||24,026,457|
|Orbimed Advisors, LLC||6,402,800||2014-09-30||4.86||0.24||22,858,000|
|State Street Corp||6,333,937||2014-09-30||4.80||0.00||22,608,000|
|BlackRock Fund Advisors||4,646,266||2014-09-30||3.52||0.00||16,587,000|
|Vanguard Group, Inc.||3,951,271||2014-09-30||3.00||0.00||14,106,000|